CDC Study Shows Effectiveness of RSV Immunization for Infants

New CDC data reveals that nirsevimab, a long-acting monoclonal antibody, is highly effective (90%) in preventing respiratory syncytial virus (RSV)-related hospitalizations in infants during their first potential exposure season. This season marks the initial availability of nirsevimab for infant protection against severe RSV. The CDC recommends its use for infants entering their first RSV season if the mother did not receive the maternal RSV vaccine.

The CDC emphasizes nirsevimab and maternal RSV vaccines as crucial tools for infant protection, with recommendations for either infant immunization or maternal vaccination during weeks 32-36 of pregnancy if applicable. Monitoring of safety and effectiveness for both vaccines continues. Read more from the CDC here.